对患有甲状腺自身免疫的不孕妇女进行卵胞浆内单精子注射与体外受精的比较

IF 5.8 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Thyroid Pub Date : 2024-06-01 Epub Date: 2024-05-02 DOI:10.1089/thy.2023.0676
Ning Huang, Lixue Chen, Zhiqiang Yan, Lin Zeng, Haining Wang, Hongbin Chi, Jie Qiao
{"title":"对患有甲状腺自身免疫的不孕妇女进行卵胞浆内单精子注射与体外受精的比较","authors":"Ning Huang, Lixue Chen, Zhiqiang Yan, Lin Zeng, Haining Wang, Hongbin Chi, Jie Qiao","doi":"10.1089/thy.2023.0676","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Background:</i></b> It has been reported that intracytoplasmic sperm injection (ICSI) may be the preferred fertilization method for women with thyroid autoimmunity (TAI) seeking assisted reproduction. We compared the reproductive outcomes of women with TAI who were treated with ICSI compared with <i>in vitro</i> fertilization (IVF). <b><i>Methods:</i></b> In this retrospective cohort study, we included women with infertility who were referred to the Reproductive Centre of Peking University Third Hospital for their first IVF/ICSI and embryo transfer (ET) treatment cycle from January 2019 to February 2021. In total, 2171 and 743 women with TAI underwent IVF and ICSI, respectively, while 8702 and 2668 women without TAI underwent IVF and ICSI, respectively. We examined the cumulative live birth rate (primary outcome) from the initiated stimulative cycle as well as the secondary outcomes of fertilization rate, rates of clinical pregnancy, and live birth after the first ET cycle. We compared the reproductive outcomes of women treated with IVF and ICSI according to TAI status. Multivariable logistic regression analyses were performed to adjust for relevant confounders. <b><i>Results:</i></b> Women who underwent ICSI had significantly higher fertilization rates than those who underwent IVF (median [interquartile range]: 0.6 [0.5-0.8] in the TAI-positive and IVF group vs. 0.7 [0.5-0.8] in the TAI-positive and ICSI group vs. 0.6 [0.5-0.8] the TAI-negative and IVF group vs. 0.7 [0.5-0.8] in the TAI-negative and ICSI group, <i>p</i> < 0.001). However, the rates of cumulative live births, clinical pregnancies, and live births were significantly lower among women with TAI who underwent ICSI than those who underwent IVF (cumulative live birth: 51.8% vs. 47%, adjusted odds ratio [aOR]: 0.80 [confidence interval, CI: 0.67-0.97]; clinical pregnancy: 43.0% vs. 38.8%, aOR: 0.81 [CI: 0.67-0.97]; live birth: 36.2% vs. 32.4%, aOR: 0.81 [CI: 0.66-0.98]). <b><i>Conclusion:</i></b> We observed that the use of ICSI in women with TAI was not associated with better assisted reproductive outcomes compared with IVF. Further prospective clinical trials are needed to confirm our findings.</p>","PeriodicalId":23016,"journal":{"name":"Thyroid","volume":" ","pages":"764-773"},"PeriodicalIF":5.8000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Intracytoplasmic Sperm Injection Versus <i>In vitro</i> Fertilization in Infertile Women with Thyroid Autoimmunity.\",\"authors\":\"Ning Huang, Lixue Chen, Zhiqiang Yan, Lin Zeng, Haining Wang, Hongbin Chi, Jie Qiao\",\"doi\":\"10.1089/thy.2023.0676\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b><i>Background:</i></b> It has been reported that intracytoplasmic sperm injection (ICSI) may be the preferred fertilization method for women with thyroid autoimmunity (TAI) seeking assisted reproduction. We compared the reproductive outcomes of women with TAI who were treated with ICSI compared with <i>in vitro</i> fertilization (IVF). <b><i>Methods:</i></b> In this retrospective cohort study, we included women with infertility who were referred to the Reproductive Centre of Peking University Third Hospital for their first IVF/ICSI and embryo transfer (ET) treatment cycle from January 2019 to February 2021. In total, 2171 and 743 women with TAI underwent IVF and ICSI, respectively, while 8702 and 2668 women without TAI underwent IVF and ICSI, respectively. We examined the cumulative live birth rate (primary outcome) from the initiated stimulative cycle as well as the secondary outcomes of fertilization rate, rates of clinical pregnancy, and live birth after the first ET cycle. We compared the reproductive outcomes of women treated with IVF and ICSI according to TAI status. Multivariable logistic regression analyses were performed to adjust for relevant confounders. <b><i>Results:</i></b> Women who underwent ICSI had significantly higher fertilization rates than those who underwent IVF (median [interquartile range]: 0.6 [0.5-0.8] in the TAI-positive and IVF group vs. 0.7 [0.5-0.8] in the TAI-positive and ICSI group vs. 0.6 [0.5-0.8] the TAI-negative and IVF group vs. 0.7 [0.5-0.8] in the TAI-negative and ICSI group, <i>p</i> < 0.001). However, the rates of cumulative live births, clinical pregnancies, and live births were significantly lower among women with TAI who underwent ICSI than those who underwent IVF (cumulative live birth: 51.8% vs. 47%, adjusted odds ratio [aOR]: 0.80 [confidence interval, CI: 0.67-0.97]; clinical pregnancy: 43.0% vs. 38.8%, aOR: 0.81 [CI: 0.67-0.97]; live birth: 36.2% vs. 32.4%, aOR: 0.81 [CI: 0.66-0.98]). <b><i>Conclusion:</i></b> We observed that the use of ICSI in women with TAI was not associated with better assisted reproductive outcomes compared with IVF. Further prospective clinical trials are needed to confirm our findings.</p>\",\"PeriodicalId\":23016,\"journal\":{\"name\":\"Thyroid\",\"volume\":\" \",\"pages\":\"764-773\"},\"PeriodicalIF\":5.8000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Thyroid\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1089/thy.2023.0676\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/5/2 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thyroid","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/thy.2023.0676","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/2 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

背景:据报道,卵胞浆内单精子显微注射(ICSI)可能是甲状腺自身免疫(TAI)妇女寻求辅助生殖的首选受精方法。我们比较了接受卵胞浆内单精子显微注射(ICSI)和体外受精(IVF)治疗的女性甲状腺自身免疫患者的生殖结果。方法:在这项回顾性队列研究中,我们纳入了2019年1月至2021年2月期间转诊至北京大学第三医院生殖中心接受首个IVF/ICSI和胚胎移植(ET)治疗周期的不孕症女性。其中,分别有2171名和743名患有TAI的女性接受了IVF和ICSI治疗,而分别有8702名和2668名未患有TAI的女性接受了IVF和ICSI治疗。我们研究了从启动刺激周期开始的累积活产率(主要结果),以及受精率、临床妊娠率和第一个 ET 周期后的活产率等次要结果。我们根据 TAI 状态比较了接受体外受精和卵胞浆内单精子显微注射治疗的妇女的生殖结果。我们进行了多变量逻辑回归分析,以调整相关混杂因素。结果显示接受卵胞浆内单精子显微注射的妇女的受精率明显高于接受体外受精的妇女(中位数[四分位距]:0.6[0.5-0.6]):TAI阳性和IVF组为0.6[0.5-0.8],TAI阳性和ICSI组为0.7[0.5-0.8],TAI阴性和IVF组为0.6[0.5-0.8],TAI阴性和ICSI组为0.7[0.5-0.8],P < 0.001)。然而,接受 ICSI 的 TAI 妇女的累积活产率、临床妊娠率和活产率均显著低于接受 IVF 的妇女(累积活产率:51.8% vs. 47%,调整赔率比 [aOR]:0.80 [置信区间,CI:0.67-0.97];临床妊娠:43.0% 对 38.8%,aOR:0.81 [CI:0.67-0.97];活产:36.2% 对 32.4%,aOR:0.81 [CI:0.66-0.98])。结论我们观察到,与体外受精相比,TAI 妇女使用 ICSI 与更好的辅助生殖结果无关。需要进一步的前瞻性临床试验来证实我们的研究结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Intracytoplasmic Sperm Injection Versus In vitro Fertilization in Infertile Women with Thyroid Autoimmunity.

Background: It has been reported that intracytoplasmic sperm injection (ICSI) may be the preferred fertilization method for women with thyroid autoimmunity (TAI) seeking assisted reproduction. We compared the reproductive outcomes of women with TAI who were treated with ICSI compared with in vitro fertilization (IVF). Methods: In this retrospective cohort study, we included women with infertility who were referred to the Reproductive Centre of Peking University Third Hospital for their first IVF/ICSI and embryo transfer (ET) treatment cycle from January 2019 to February 2021. In total, 2171 and 743 women with TAI underwent IVF and ICSI, respectively, while 8702 and 2668 women without TAI underwent IVF and ICSI, respectively. We examined the cumulative live birth rate (primary outcome) from the initiated stimulative cycle as well as the secondary outcomes of fertilization rate, rates of clinical pregnancy, and live birth after the first ET cycle. We compared the reproductive outcomes of women treated with IVF and ICSI according to TAI status. Multivariable logistic regression analyses were performed to adjust for relevant confounders. Results: Women who underwent ICSI had significantly higher fertilization rates than those who underwent IVF (median [interquartile range]: 0.6 [0.5-0.8] in the TAI-positive and IVF group vs. 0.7 [0.5-0.8] in the TAI-positive and ICSI group vs. 0.6 [0.5-0.8] the TAI-negative and IVF group vs. 0.7 [0.5-0.8] in the TAI-negative and ICSI group, p < 0.001). However, the rates of cumulative live births, clinical pregnancies, and live births were significantly lower among women with TAI who underwent ICSI than those who underwent IVF (cumulative live birth: 51.8% vs. 47%, adjusted odds ratio [aOR]: 0.80 [confidence interval, CI: 0.67-0.97]; clinical pregnancy: 43.0% vs. 38.8%, aOR: 0.81 [CI: 0.67-0.97]; live birth: 36.2% vs. 32.4%, aOR: 0.81 [CI: 0.66-0.98]). Conclusion: We observed that the use of ICSI in women with TAI was not associated with better assisted reproductive outcomes compared with IVF. Further prospective clinical trials are needed to confirm our findings.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Thyroid
Thyroid 医学-内分泌学与代谢
CiteScore
12.30
自引率
6.10%
发文量
195
审稿时长
6 months
期刊介绍: This authoritative journal program, including the monthly flagship journal Thyroid, Clinical Thyroidology® (monthly), and VideoEndocrinology™ (quarterly), delivers in-depth coverage on topics from clinical application and primary care, to the latest advances in diagnostic imaging and surgical techniques and technologies, designed to optimize patient care and outcomes. Thyroid is the leading, peer-reviewed resource for original articles, patient-focused reports, and translational research on thyroid cancer and all thyroid related diseases. The Journal delivers the latest findings on topics from primary care to clinical application, and is the exclusive source for the authoritative and updated American Thyroid Association (ATA) Guidelines for Managing Thyroid Disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信